FDA Removes 12 Peptides from 503A Category 2 : r us_pharmacies FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies Peptide power laws Chief Longevity Officer Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved